MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure

European Journal of Heart Failure

Volumn 17, Issue 4, 2015, Pages 405-415

  Watson, Chris J ^a,b   Gupta, Shashi K ^c   O'Connell, Eoin ^b   Thum, Sabrina ^c   Glezeva, Nadezhda ^a   Fendrich, Jasmin ^c   Gallagher, Joe ^b   Ledwidge, Mark ^b   Grote Levi, Lea ^c   McDonald, Kenneth ^b   Thum, Thomas ^c,d  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST MICHAEL'S HOSPITAL   (Ireland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Biomarker; Diagnosis; Ejection fraction; Heart failure; MicroRNA; Natriuretic peptide

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; MICRORNA; MICRORNA 146A; MICRORNA 221; MICRORNA 30C; MICRORNA 328; MICRORNA 375; UNCLASSIFIED DRUG; NATRIURETIC FACTOR;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PREDICTIVE VALUE; PRIORITY JOURNAL; BLOOD; HEART STROKE VOLUME; HEART VENTRICLE; HEART VENTRICLE FUNCTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NATRIURETIC PEPTIDES; STROKE VOLUME; VENTRICULAR DYSFUNCTION;

EID: 84926151941     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.244     Document Type: Article

References (30)

1. Seferovic PM, Stoerk S, Filippatos G, Mareev V, Kavoliuniene A, Ristic AD, Ponikowski P, McMurray J, Maggioni A, Ruschitzka F, van Veldhuisen DJ, Coats A, Piepoli M, McDonagh T, Riley J, Hoes A, Pieske B, Dobric M, Papp Z, Mebazaa A, Parissis J, Ben Gal T, Vinereanu D, Brito D, Altenberger J, Gatzov P, Milinkovic I, Hradec J, Trochu JN, Amir O, Moura B, Lainscak M, Comin J, Wikstrom G, Anker S,. Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail 2013; 15: 947-959.
2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS,. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402.
3. Taylor CJ, Roalfe AK, Iles R, Hobbs FD,. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur J Heart Fail 2012; 14: 176-184.
4. Fox KF, Cowie MR, Wood DA, Coats AJ, Poole-Wilson PA, Sutton GC,. A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. Eur J Heart Fail 2000; 2: 423-429.
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
6. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R,. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007; 28: 1128-1134.
7. Paulus WJ, Tschope C,. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-271.
8. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL,. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61: 1498-1506.
9. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E,. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839.
10. Bishu K, Deswal A, Chen HH, LeWinter MM, Lewis GD, Semigran MJ, Borlaug BA, McNulty S, Hernandez AF, Braunwald E, Redfield MM,. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 2012; 164: 763-770.
11. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP,. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-2150.
12. Kumarswamy R, Thum T,. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013; 113: 676-689.
13. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S,. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol 2013; 33: 206-214.
14. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K,. Natriuretic peptide-based screening and collaborative care for heart failure: The STOP-HF randomized trial. JAMA 2013; 310: 66-74.
15. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A,. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107-133.
16. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 43: 29-36.
17. Kerr KF, McClelland RL, Brown ER, Lumley T,. Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol 2011; 174: 364-374.
18. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE,. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104: 170-178, 6p following 178.
19. Wang X, Ha T, Liu L, Zou J, Zhang X, Kalbfleisch J, Gao X, Williams D, Li C,. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res 2013; 97: 432-442.
20. Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H, Mohan V,. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem 2011; 351: 197-205.
21. Feng B, Chen S, McArthur K, Wu Y, Sen S, Ding Q, Feldman RD, Chakrabarti S,. miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 2011; 60: 2975-2984.
22. Olivieri F, Lazzarini R, Recchioni R, Marcheselli F, Rippo MR, Di Nuzzo S, Albertini MC, Graciotti L, Babini L, Mariotti S, Spada G, Abbatecola AM, Antonicelli R, Franceschi C, Procopio AD,. MiR-146a as marker of senescence-associated pro-inflammatory status in cells involved in vascular remodelling. Age (Dordr) 2013; 35: 1157-1172.
23. Roldan V, Arroyo AB, Salloum-Asfar S, Manzano-Fernandez S, Garcia-Barbera N, Marin F, Vicente V, Gonzalez-Conejero R, Martinez C,. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost 2014; 112: 781-788.
24. Feng HJ, Ouyang W, Liu JH, Sun YG, Hu R, Huang LH, Xian JL, Jing CF, Zhou MJ,. Global microRNA profiles and signaling pathways in the development of cardiac hypertrophy. Braz J Med Biol Res 2014; 47: 361-368.
25. Wang C, Wang S, Zhao P, Wang X, Wang J, Wang Y, Song L, Zou Y, Hui R,. MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. J Cell Biochem 2012; 113: 2040-2046.
26. Li C, Li X, Gao X, Zhang R, Zhang Y, Liang H, Xu C, Du W, Liu X, Ma N, Xu Z, Wang L, Chen X, Lu Y, Ju J, Yang B, Shan H,. MicroRNA-328 as a regulator of cardiac hypertrophy. Int J Cardiol 2014; 173: 268-276.
27. He F, Lv P, Zhao X, Wang X, Ma X, Meng W, Meng X, Dong S,. Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem 2014; 394: 137-144.
28. Li X., MiR-375, a microRNA related to diabetes. Gene 2014; 533: 1-4.
29. Erener S, Mojibian M, Fox JK, Denroche HC, Kieffer TJ,. Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 2013; 154: 603-608.
30. Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM,. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-1147.